BSL2

Gilbane Completes Two New Class A, Mixed-Use Life Sciences Buildings in Massachusetts

Retrieved on: 
Tuesday, January 2, 2024
Atmosphere, Prospect Street, USQ, MBTA, Ink, Research, Glass, Gilbane, Inc., Silver, Environment, Certification, Heart, History, Air handler, Gilbane Building Company, JLL, Commonwealth, LEED, BSL2, Gold, Coffee, SGA, SF, MEP

BOSTON, Jan. 2, 2024 /PRNewswire-PRWeb/ -- Gilbane Building Company is pleased to announce the successful completion of two Class A, mixed-use, life sciences facilities located just outside of Boston. Both buildings are targeting LEED certification, adding to the emerging biotechnology clusters within their respective areas.

Key Points: 
  • BOSTON, Jan. 2, 2024 /PRNewswire-PRWeb/ -- Gilbane Building Company is pleased to announce the successful completion of two Class A, mixed-use, life sciences facilities located just outside of Boston.
  • Both buildings are targeting LEED certification, adding to the emerging biotechnology clusters within their respective areas.
  • A two-story mechanical penthouse supports essential life sciences equipment.
  • "Gilbane is thrilled to deliver these state-of-the-art facilities to benefit the growing life sciences market throughout the Commonwealth," said Justin MacEachern, vice president and business unit leader for Gilbane in Massachusetts.

WuXi Vaccines' First Drug Substance Facility in China Released for GMP Manufacturing

Retrieved on: 
Friday, July 28, 2023
Vaccine, GMP, BSL2, CHO, DS, CDMO, CGMP, WHO, FDA, Safety

SUZHOU, China, July 27, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou, China.

Key Points: 
  • SUZHOU, China, July 27, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou, China.
  • DS production has already begun at the facility.
  • The DS facility employs the proven and reliable CHO cell-culture platform, and utilizes single-use bioreactors up to 1000L – a combination that enhances both the efficiency and quality of drug substance production.
  • Mr. Jian Dong, CEO of WuXi Vaccines, commented, "The release of the drug substance facility at our Suzhou site and the start of manufacturing marks a major milestone for WuXi Vaccines.

WuXi Vaccines' First Drug Substance Facility in China Released for GMP Manufacturing

Retrieved on: 
Friday, July 28, 2023
Vaccine, GMP, BSL2, CHO, DS, CDMO, CGMP, WHO, FDA, Safety

SUZHOU, China, July 28, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou, China.

Key Points: 
  • SUZHOU, China, July 28, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou, China.
  • DS production has already begun at the facility.
  • The DS facility employs the proven and reliable CHO cell-culture platform, and utilizes single-use bioreactors up to 1000L – a combination that enhances both the efficiency and quality of drug substance production.
  • Mr. Jian Dong, CEO of WuXi Vaccines, commented, "The release of the drug substance facility at our Suzhou site and the start of manufacturing marks a major milestone for WuXi Vaccines.

Integral Molecular Launches New Product Lines of Safe Reporter Viruses for Vaccine Development and Pandemic Preparedness

Retrieved on: 
Thursday, October 20, 2022
Influenza, Omicron, Therapy, Fever Dream, Virus, Vaccine, Laboratory, Severe acute respiratory syndrome coronavirus 2, Antibody, RVP, Research, Collection, Path integral molecular dynamics, Cancer, BSL4, Reporter virus particles, Doctor of Philosophy, Industry, Virology, BSL2, Diabetes, Membrane protein, COVID-19, Degenerative disease, Zika fever

Integral Molecular's new RVP offerings feature influenza A H5N1, Ebola virus, and Marburg virus.

Key Points: 
  • Integral Molecular's new RVP offerings feature influenza A H5N1, Ebola virus, and Marburg virus.
  • Integral Molecular has also created custom variants, as well as thousands of mutations in this safe RVP format to enable prediction of viral escape and the creation of better vaccines.
  • "With 20 years of experience studying viruses and vaccines, we are excited to launch new products that enable faster and safer vaccine development against the world's deadliest viruses," said Sharon Willis, PhD, co-founder of Integral Molecular.
  • Integral Molecular's broad range of RVPs also includes a selection of influenza A and B seasonal strains, dengue, Zika, and chikungunya viruses.

KCAS Expands Its Transatlantic Presence with the Acquisition of France-based Active Biomarkers

Retrieved on: 
Monday, September 12, 2022
Biotechnology, Technology, Other Health, Health, Pharmaceutical, Oncology, Other Science, Other Technology, Research, Genetics, Science, MSD, Partner, Inflammation, PK, Vitruvian Partners, GLP, Infection, ELISA, Luminex, Neurodegeneration, Acquisition, Biomarker, Growth, Partnership, GCLP, Investment, CEO, CRO, BSL2, ELLA, Science, Drug development, KCAS, ISO 9001:2015, Multimedia, Flow cytometry, ISO, ELISpot, Fine chemical, Kansas City metropolitan area, Vitruvian Man

Active Biomarkers is a renowned assay development and specialty bioanalytical laboratory with expertise in oncology, infectious disease, inflammation and neurodegenerative disorders.

Key Points: 
  • Active Biomarkers is a renowned assay development and specialty bioanalytical laboratory with expertise in oncology, infectious disease, inflammation and neurodegenerative disorders.
  • The acquisition of Active Biomarkers is the second in 2022 by KCAS.
  • The acquisition of Active Biomarkers gives our combined clients access to further scientific expertise and support in both markets regionally and internationally.
  • The acquisition of Active Biomarkers by KCAS builds on the excellent foundation KCAS has built in the US and supports the increasingly international needs of the companys growing pharmaceutical and biotech clients.

Bulfinch Leases 40,000 Square Feet to LabShares

Retrieved on: 
Thursday, December 9, 2021
Biotechnology, Science, Health, Other Science, Newton, SVP, HPLC, Biotechnology, QT, Massachusetts Turnpike, Safety, Restaurant, Labshare, I-95, CEO, Microscope, BSL2, Multimedia, List of highways numbered 128, Flow cytometry, The Bulfinch Companies, Coffee, Acquisition, SF, Western blot, Retail, Tunnel

The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and LabShares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge Park in Newton, Massachusetts, with an additional 25,000 square feet of space, bringing LabShares total leased premises at the complex to approximately 40,000 square feet.

Key Points: 
  • The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and LabShares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge Park in Newton, Massachusetts, with an additional 25,000 square feet of space, bringing LabShares total leased premises at the complex to approximately 40,000 square feet.
  • LabShares is a flexible, turnkey lab and coworking office space for life-science and biotech startups.
  • We are thrilled to support LabShares expansion at Chapel Bridge Park, stated Mike Wilcox, SVP, Director of Leasing at Bulfinch.
  • Bulfinch continues to expand our life science portfolio and seek partnerships with tenants like LabShares that help life science start-ups meet speed to market demands.

Rapid Advancements of Innovative Antiviral - COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

Retrieved on: 
Monday, October 11, 2021
Acumen, NASDAQ, BSL4, Degenerative disease, BNTX, Infection, Risk, LLY, Pfizer, Adult, GFP, Death, BSL2, Regeneron Pharmaceuticals, CAGR, COVID-19, ACE2, Food, Cell, Eli Lilly and Company, Pseudotyping, Influenza-like illness, Drug development, EUA, Marketing, Growth, Mortality, Conditional sentence, MRK, FDA, Virus, BioNTech, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Globe, Consultant, PFE, Data monitoring committee, Laboratory, RNA transfection, Microscopy, Severe acute respiratory syndrome coronavirus 2, News, BSL3, NYSE, Coronavirus, Solution, Partnership, PALM, Patient, Government, Hospital, Nasdaq, Pharmaceutical industry, Vaccine

Substantial increase in number of patients suffering from viral infections and increasing R&D activities by major players for development of novel products are major factors expected to drive the growth of global antiviral drugs market.

Key Points: 
  • Substantial increase in number of patients suffering from viral infections and increasing R&D activities by major players for development of novel products are major factors expected to drive the growth of global antiviral drugs market.
  • In addition, increasing partnership and agreements between regional and international players is expected to support the revenue transaction of the target market.
  • The market in North America is expected to account for major revenue share in the global drugs market due to rise in number of patients suffering from chronic diseases.
  • In addition, availability of advanced infrastructure in the country, increasing R&D activities, and focus on introduction of innovative drugs are factors expected to impact the growth of antiviral drugs market."

Rapid Advancements of Innovative Antiviral - COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market

Retrieved on: 
Monday, October 11, 2021
Acumen, NASDAQ, BSL4, Degenerative disease, BNTX, Infection, Risk, LLY, Pfizer, Adult, GFP, Death, BSL2, Regeneron Pharmaceuticals, CAGR, COVID-19, ACE2, Food, Cell, Eli Lilly and Company, Pseudotyping, Influenza-like illness, Drug development, EUA, Marketing, Growth, Mortality, Conditional sentence, MRK, FDA, Virus, BioNTech, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Globe, Consultant, PFE, Data monitoring committee, Laboratory, RNA transfection, Microscopy, Severe acute respiratory syndrome coronavirus 2, News, BSL3, NYSE, Coronavirus, Solution, Partnership, PALM, Patient, Government, Hospital, Nasdaq, Pharmaceutical industry, Vaccine

PALM BEACH,  Fla., Oct. 11, 2021 /PRNewswire/ -- With the arrival of the COVID-19 virus, the antivirals market had all eyes watching the ongoing frenetic rush to find a cure or at least a therapy. That race has not yet abated… not at all! Substantial increase in number of patients suffering from viral infections and increasing R&D activities by major players for development of novel products are major factors expected to drive the growth of global antiviral drugs market. In US the proportion of outpatient visits for influenza-like illness increased. In fact, a report from Acumen Research and Consulting projected that the global antiviral drugs market is anticipated to grow at a CAGR of around 3.7% during the forecast period 2020 to 2027 and to reach around US$ 74.7 billion by 2027.  The report added: "Increase in pandemic effect across the globe and rise in mortality rate are pressurizing the government to take necessary steps for drug development. Major players are focused on conducting rapid clinical trials for development of new drug, along with early product approval from the government as a preventive measure for treatment of covid-19 patients are factors cumulatively expected to augment the market growth."  Active Biotechs in the markets today include:  NanoViricides, Inc. (NYSE: NNVC), Pfizer Inc. (NYSE: PFE), Merck (NYSE: MRK), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Eli Lilly and Company (NYSE: LLY).

Key Points: 
  • Substantial increase in number of patients suffering from viral infections and increasing R&D activities by major players for development of novel products are major factors expected to drive the growth of global antiviral drugs market.
  • In addition, increasing partnership and agreements between regional and international players is expected to support the revenue transaction of the target market.
  • The market in North America is expected to account for major revenue share in the global drugs market due to rise in number of patients suffering from chronic diseases.
  • In addition, availability of advanced infrastructure in the country, increasing R&D activities, and focus on introduction of innovative drugs are factors expected to impact the growth of antiviral drugs market."